Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Sesen Bio, Inc. Sesen Bio Stockholders Approve Merger with Carisma Therapeutics March 02, 2023 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results February 28, 2023 From Sesen Bio, Inc. Via Business Wire Tickers SESN Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma February 21, 2023 From Sesen Bio, Inc. Via Business Wire Tickers SESN Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting February 16, 2023 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger February 16, 2023 From Sesen Bio, Inc. Via Business Wire Tickers SESN BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics February 15, 2023 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger February 14, 2023 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger February 02, 2023 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio Receives NASDAQ Delisting Notice January 30, 2023 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders January 26, 2023 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics January 19, 2023 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics January 04, 2023 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger December 29, 2022 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio and Carisma Therapeutics Announce Merger Agreement September 21, 2022 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™ December 09, 2021 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum™ August 02, 2021 From Sesen Bio, Inc. Via Business Wire Tickers SESN Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 18, 2021 From Sesen Bio, Inc. Via Business Wire Tickers SESN Dr. Thomas Cannell, President and CEO of Sesen Bio, to Participate in Fireside Chat at the 2021 Jefferies Virtual Healthcare Conference May 27, 2021 From Sesen Bio, Inc. Via Business Wire Tickers SESN Dr. Thomas Cannell, President and CEO of Sesen Bio, and Dr. Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity “Horizons in Oncology” Virtual Conference April 08, 2021 From Sesen Bio, Inc. Via Business Wire Tickers SESN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.